AGA临床实践更新:无创生物标志物在非酒精性脂肪性肝病评估与管理中的作用专家综述
美国胃肠病学会(AGA)发布临床实践更新,为临床医生提供无创检测(NITs)在非酒精性脂肪性肝病(NAFLD)评估与管理中的指导。NAFLD影响全球近30%人口,但仅少数患者出现肝脏相关结局,因此初始评估时识别进展风险至关重要。该更新基于文献综述与专家共识提出8条最佳实践建议,未对证据质量或推荐强度进行正式评级。
要点
- NITs可用于NAFLD诊断评估中的风险分层。
- Fibrosis 4指数<1.3对晚期肝纤维化有强阴性预测价值,可用于排除。
- Fibrosis 4指数>1.3者,推荐联合2种及以上NITs(血清和/或影像)进行分期与风险分层。
核心结论
- NITs有助于NAFLD患者的风险分层和疾病进展的纵向评估。
- 最佳实践建议基于文献综述与专家共识,未进行系统评价,未对证据质量或推荐强度进行正式评级。
研究设计与样本
- 本专家综述由AGA临床实践更新委员会和AGA理事会委托并批准,经内部同行评议和Gastroenterology标准外部同行评议。
- 最佳实践建议来自已发表文献综述和专家意见,未进行系统评价。
主要发现
- NAFLD影响全球近30%人口,是终末期肝病和肝脏相关医疗资源利用的日益增长的原因。
- 仅少数NAFLD患者出现肝脏相关结局,初始评估时评估预后和识别疾病进展及不良临床结局风险增加者至关重要。
- 肝活检组织学检查是评估预后和监测疾病的参考标准,但肝活检及其判读存在许多局限性,限制了其在常规实践中的应用。
关键数值与推荐
- 最佳实践建议1:NITs可用于NAFLD诊断评估中的风险分层。
- 最佳实践建议2:Fibrosis 4指数评分<1.3与晚期肝纤维化强阴性预测值相关,可用于排除NAFLD患者的晚期肝纤维化。
- 最佳实践建议3:对于Fibrosis 4指数评分>1.3的NAFLD患者,优先使用联合2种或以上NITs(联合血清生物标志物和/或基于影像的生物标志物)进行分期和风险分层。
- 最佳实践建议4:按照制造商规格使用NITs(例如不用于腹水或起搏器患者)可最大程度减少不一致结果和不良事件的风险。
- 最佳实践建议5:NITs应结合相关临床数据(如体格检查、生化、影像学和内镜)进行解读,以优化识别晚期肝纤维化患者的阳性预测值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本专家综述未进行系统评价,最佳实践建议未对证据质量或推荐强度进行正式评级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review is to provide clinicians with guidance on the use of noninvasive tests (NITs) in the evaluation and management of patients with nonalcoholic fatty liver disease (NAFLD). NAFLD affects nearly 30% of the global population and is a growing cause of end-stage liver disease and liver-related health care resource utilization. However, only a minority of all patients with NAFLD experience a liver-related outcome. It is therefore critically important for clinicians to assess prognosis and identify those with increased risk of disease progression and negative clinical outcomes at the time of initial assessment. It is equally important to assess disease trajectory over time, particularly in response to currently available therapeutic approaches. The reference standard for assessment of prognosis and disease monitoring is histologic examination of liver biopsy specimens. There are, however, many limitations of liver biopsies and their reading that have limited their use in routine practice. The utilization of NITs facilitates risk stratification of patients and longitudinal assessment of disease progression for patients with NAFLD. This clinical update provides best practice advice based on a review of the literature on the utilization of NITs in the management of NAFLD for clinicians. Accordingly, a combination of available evidence and consensus-based expert opinion, without formal rating of the strength and quality of the evidence, was used to develop these best practice advice statements. METHODS: This Expert Review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. These best practice advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these best practice advice statements do not carry formal ratings of the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: NITs can be used for risk stratification in the diagnostic evaluation of patients with NAFLD. BEST PRACTICE ADVICE 2: A Fibrosis 4 Index score <1.3 is associated with strong negative predictive value for advanced hepatic fibrosis and may be useful for exclusion of advanced hepatic fibrosis in patients with NAFLD. BEST PRACTICE ADVICE 3: A combination of 2 or more NITs combining serum biomarkers and/or imaging-based biomarkers is preferred for staging and risk stratification of patients with NAFLD whose Fibrosis 4 Index score is >1.3. BEST PRACTICE ADVICE 4: Use of NITs in accordance with manufacturer's specifications (eg, not in patients with ascites or pacemakers) can minimize risk of discordant results and adverse events. BEST PRACTICE ADVICE 5: NITs should be interpreted with context and consideration of pertinent clinical data (eg, physical examination, biochemical, radiographic, and endoscopic) to optimize positive predictive value in the identification of patients with advanced fibrosis. BEST PRACTICE ADVICE 6: Liver biopsy should be considered for patients with NIT results that are indeterminate or discordant; conflict with other clinical, laboratory, or radiologic findings; or when alternative etiologies for liver disease are suspected. BEST PRACTICE ADVICE 7: Serial longitudinal monitoring using NITs for assessment of disease progression or regression may inform clinical management (ie, response to lifestyle modification or therapeutic intervention). BEST PRACTICE ADVICE 8: Patients with NAFLD and NITs results suggestive of advanced fibrosis (F3) or cirrhosis (F4) should be considered for surveillance of liver complications (eg, hepatocellular carcinoma screening and variceal screening per Baveno criteria). Patients with NAFLD and NITs suggestive of advanced hepatic fibrosis (F3) or (F4), should be monitored with serial liver stiffness measurement; vibration controlled transient elastography; or magnetic resonance elastography, given its correlation with clinically significant portal hypertension and clinical decompensation.
引用
- Wattacheril JJ, Abdelmalek MF, Lim JK, et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2023. PMID: 37542503. doi:10.1053/j.gastro.2023.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。